Very low reporting rate of connective tissue diseases among coronavirus disease 2019 (Covid-19) patients and the renin-angiotensin system - An overlooked association?
作者信息
Giollo Alessandro, Cioffi Giovanni, Rossini Maurizio, Viapiana Ombretta, De Simone Giovanni
机构信息
Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy.
Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy.
出版信息
Eur J Intern Med. 2020 Oct;80:106-107. doi: 10.1016/j.ejim.2020.06.012. Epub 2020 Jun 12.
Abstract
摘要
相似文献
1
Very low reporting rate of connective tissue diseases among coronavirus disease 2019 (Covid-19) patients and the renin-angiotensin system - An overlooked association?2019冠状病毒病（Covid-19）患者中结缔组织病的报告率极低与肾素-血管紧张素系统——一种被忽视的关联？
Eur J Intern Med. 2020 Oct;80:106-107. doi: 10.1016/j.ejim.2020.06.012. Epub 2020 Jun 12.
2
COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.心力衰竭背景下COVID-19对肾素-血管紧张素系统的干扰
mBio. 2020 May 22;11(3):e00946-20. doi: 10.1128/mBio.00946-20.
3
COVID-19 challenging cell biology.新冠病毒对细胞生物学构成挑战。
Protoplasma. 2020 May;257(3):619-620. doi: 10.1007/s00709-020-01506-z. Epub 2020 Apr 24.
4
The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.高血压、血管紧张素转换酶2（ACE-2）与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）之间的相互作用：新出现的数据成为2019冠状病毒病（COVID-19）“迷宫”中的“阿里阿德涅之线” 。
Hellenic J Cardiol. 2020 Jan-Feb;61(1):31-33. doi: 10.1016/j.hjc.2020.05.003. Epub 2020 May 22.
5
Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.2019冠状病毒病大流行期间肾素-血管紧张素系统阻滞剂的使用：早期指南及不断演变的证据
Can J Cardiol. 2020 Aug;36(8):1180-1182. doi: 10.1016/j.cjca.2020.05.033. Epub 2020 Jun 2.
6
SARS-CoV-2 & Covid-19: Key-Roles of the 'Renin-Angiotensin' System / Vitamin D Impacting Drug and Vaccine Developments.严重急性呼吸综合征冠状病毒2型与新冠肺炎：“肾素-血管紧张素”系统的关键作用/维生素D对药物和疫苗研发的影响
Infect Disord Drug Targets. 2020;20(3):348-349. doi: 10.2174/1871526520999200505174704.
7
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?肾素-血管紧张素系统与严重急性呼吸综合征冠状病毒 2 感染的相关性：我们了解多少？
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
8
Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）与血管紧张素转换酶2的结合：临床意义
Cardiovasc Res. 2020 Jun 1;116(7):e87-e89. doi: 10.1093/cvr/cvaa096.
9
Effects of Renin-Angiotensin Inhibition on ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Protease Serine 2) Expression: Insights Into COVID-19.肾素-血管紧张素抑制对ACE2（血管紧张素转换酶2）和TMPRSS2（跨膜丝氨酸蛋白酶2）表达的影响：对2019冠状病毒病的见解
Hypertension. 2020 Oct;76(4):e29-e30. doi: 10.1161/HYPERTENSIONAHA.120.15782. Epub 2020 Jul 14.
10
Is COVID-19 more severe in older men?新冠病毒肺炎在老年男性中病情更严重吗？
Postgrad Med J. 2020 Jul;96(1137):426. doi: 10.1136/postgradmedj-2020-137867. Epub 2020 May 13.
本文引用的文献
1
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.ACE2 缺乏与 SARS-CoV-2 感染之间的关键联系。
Eur J Intern Med. 2020 Jun;76:14-20. doi: 10.1016/j.ejim.2020.04.037. Epub 2020 Apr 20.
2
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.17例长期接受羟氯喹治疗的系统性红斑狼疮患者的2019冠状病毒病（COVID-19）临床病程
Ann Rheum Dis. 2020 Jun;79(6):837-839. doi: 10.1136/annrheumdis-2020-217566. Epub 2020 Apr 24.
3
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.一系列接受免疫抑制靶向治疗的慢性关节炎患者的 COVID-19 临床病程。
Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2.
4
COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.一名接受托珠单抗治疗系统性硬化症相关间质性肺病的系统性硬化症患者感染了新冠病毒。
Ann Rheum Dis. 2020 May;79(5):668-669. doi: 10.1136/annrheumdis-2020-217442. Epub 2020 Apr 2.
5
Speculation is not evidence: antihypertensive therapy and COVID-19.推测并非证据：抗高血压治疗与新型冠状病毒肺炎
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):133-134. doi: 10.1093/ehjcvp/pvaa021.
6
Angiotensin Converting Enzyme 2: A Double-Edged Sword.血管紧张素转换酶2：一把双刃剑。
Circulation. 2020 Aug 4;142(5):426-428. doi: 10.1161/CIRCULATIONAHA.120.047049. Epub 2020 Mar 26.
7
Sex difference and smoking predisposition in patients with COVID-19.新型冠状病毒肺炎患者的性别差异与吸烟易感性
Lancet Respir Med. 2020 Apr;8(4):e20. doi: 10.1016/S2213-2600(20)30117-X. Epub 2020 Mar 11.
8
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
9
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?可溶性血管紧张素转化酶 2：冠状病毒感染治疗的潜在方法？
Clin Sci (Lond). 2020 Mar 13;134(5):543-545. doi: 10.1042/CS20200163.
10
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.一项重组人血管紧张素转换酶 2 在急性呼吸窘迫综合征中的临床试验。
Crit Care. 2017 Sep 7;21(1):234. doi: 10.1186/s13054-017-1823-x.
Zotero 插件